Sugi Predict

Sugi Predict / Compounds / SCHEMBL701746

SCHEMBL701746

SCHEMBL701746

CCOC(=O)[C@H](C)OS(=O)(=O)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.38
▸ HSD17B10 Q99714 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ IDH1 O75874 1/20 0.32
▸ GRM2 Q14416 1/20 0.32
▸ PIN1 Q13526 1/20 0.32
▸ TSHR P16473 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ ATM Q13315 1/20 0.31
▸ MGAM O43451 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ SI P14410 1/20 0.31
▸ MGAM2 Q2M2H8 1/20 0.31
▸ CXCR2 P25025 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324715 1.00 POLB (0.38) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL324716 1.00 POLB (0.38) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL7285869 0.84 TSHR (0.36) MAPTSMN1; SMN2ALDH1A1TSHRGAA
SCHEMBL27029062 0.83 ALDH1A1 (0.40) POLBMAPTSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL8397971 0.82 POLB (0.36) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL8397975 0.82 POLB (0.36) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL16584183 0.81 CA14 (0.41) SMN1; SMN2KMT2ACXCR2MEN1
SCHEMBL2797628 0.81 CA14 (0.41) SMN1; SMN2KMT2ACXCR2MEN1
SCHEMBL2598240 0.81 CA14 (0.41) SMN1; SMN2KMT2ACXCR2MEN1
SCHEMBL2326461 0.80 HSD17B10 (0.35) POLBHSD17B10MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104409-A1 MULTIMERIC MANGANESE CONTRAST AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2026-05-21 — — WO disclosed
EP-4741400-A1 MULTIMERIC MANGANESE CONTRAST AGENTS Bayer Aktiengesellschaft (DE) 2026-05-13 — — EP disclosed
US-20250108123-A1 COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2025-04-03 — — US disclosed
US-20240116909-A1 NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-04-11 — — US disclosed
US-20220144775-A1 HYDRAZIDE COMPOUND AND KINASE INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2022-05-12 — — US disclosed
US-9643984-B2 Method for the preparation of [1,2,4]-triazolo[4,3-a]pyridines AMGEN INC. (US) 2017-05-09 — — US disclosed
US-20160347769-A1 METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES AMGEN INC. 2016-12-01 — — US disclosed
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 — — US disclosed
US-9115151-B2 Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof ABBVIE INC. (US) 2015-08-25 — — US disclosed
US-9115151-B2 Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof ABBVIE INC. (US) 2015-08-25 — — US disclosed
EP-1937651-A1 NNRT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 — — EP disclosed
WO-2007039463-A1 NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 — — WO disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 — — US disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 — — US disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 — — US disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 — — US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 — — EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 — — WO disclosed
CN-1084743-C Muscarinic antagonists SCHERING CORP (US) 2002-05-15 — — CN disclosed
CN-1232462-A Muscarinic antagonists SCHERING CORP (US) 1999-10-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, HPRT1, RTF1 POLB 134/4885HSD17B10 1282/4885MAPT 1783/4885
US-20220144775-A1 HYDRAZIDE COMPOUND AND KINASE INHIBITOR LATS1, LATS2, STK4 POLB 4201/4885HSD17B10 677/4885MAPT 2889/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 POLB 1031/4885HSD17B10 1604/4885MAPT 2397/4885
US-20240116909-A1 NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF STING1, CGAS, IRF3 POLB 534/4885HSD17B10 4293/4885MAPT 4818/4885
US-20250108123-A1 COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF STING1, IRF3, CGAS POLB 1070/4885HSD17B10 4267/4885MAPT 4699/4885
US-20160347769-A1 METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES H1-4, H1-5, H1-3 POLB 1990/4885HSD17B10 3707/4885MAPT 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.